Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABSW) Current Assets (2020 - 2025)

SAB Biotherapeutics' Current Assets history spans 6 years, with the latest figure at $101.1 million for Q4 2025.

  • For Q4 2025, Current Assets rose 324.73% year-over-year to $101.1 million; the TTM value through Dec 2025 reached $101.1 million, up 324.73%, while the annual FY2025 figure was $101.1 million, 324.73% up from the prior year.
  • Current Assets reached $101.1 million in Q4 2025 per SABSW's latest filing, down from $113.3 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $113.3 million in Q3 2025 to a low of $770615.0 in Q3 2021.
  • Average Current Assets over 5 years is $31.6 million, with a median of $23.0 million recorded in 2022.
  • Peak YoY movement for Current Assets: soared 3218.15% in 2022, then tumbled 85.9% in 2023.
  • A 5-year view of Current Assets shows it stood at $50.2 million in 2021, then crashed by 55.97% to $22.1 million in 2022, then skyrocketed by 166.58% to $58.9 million in 2023, then tumbled by 59.61% to $23.8 million in 2024, then surged by 324.73% to $101.1 million in 2025.
  • Per Business Quant, the three most recent readings for SABSW's Current Assets are $101.1 million (Q4 2025), $113.3 million (Q3 2025), and $9.3 million (Q2 2025).